NasdaqCM:CAPRBiotechs
Why Capricor Therapeutics (CAPR) Is Down 15.8% After Phase 3 Win And $1.5 Billion Deal
Capricor Therapeutics recently reported that its Phase 3 trial of deramiocel met both primary and secondary endpoints and entered commercialization and distribution agreements with Nippon Shinyaku covering the U.S., Japan, and Europe, with potential milestones totalling US$1.50 billion.
This combination of late-stage clinical success and a broad global partnership materially advances Capricor’s path from a purely clinical-stage company toward potential commercial execution.
We’ll now examine...